Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
Xuehua Ke(Wilmington University), Lisa A. Beck(University of Rochester Medicine), Vincent J. Willey(Wilmington University), Judith J. Stephenson(Wilmington University), Abhishek Kavati(Pfizer (United States)), Benjamin Ortiz(Harlem Hospital Center), Jonathan A. Bernstein(Bernstein Clinical Research Center), Qing Huang(The University of Texas MD Anderson Cancer Center), Liya Wang(Wilmington University), Brandee Paknis(Novartis (United States)), Debra Wertz(Wilmington University)
Cited by 8
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k